美托洛尔治疗心脏瓣膜病伴心力衰竭患者的效果观察  

Efficacy of Metoprolol in the Treatment of Heart Valve Disease with Heart Failure

作　　者：张辉[1] ZHANG Hui(Henan Chest Hospital,Zhengzhou Henan 450000,China)

机构地区：[1]河南省胸科医院

出　　处：《药品评价》2019年第19期74-75,共2页Drug Evaluation

摘　　要：目的:探讨美托洛尔治疗心脏瓣膜病伴心力衰竭的疗效。方法:以80例心脏瓣膜病伴心力衰竭患者为对象,随机抽签分为对照组和观察组(例=40),对照组给予常规治疗,观察组给予酒石酸美托洛尔治疗,比较患者治疗前与治疗1疗程后的收缩压(SBP)、舒张压(DBP)、心率及血清B型利钠肽(BNP)、血清超敏C反应蛋白(hs-CRP)水平。观察不良反应情况。结果:相较于治疗前,两组患者的上述指标水平均有所下降(P<0.05),观察组的心率、血清BNP及hs-CRP水平明显低于对照组(P<0.05);组间SBP和DBP水平比较无差异(P>0.05);观察组与对照组的不良反应比较无差异(P>0.05)。结论:对于心脏瓣膜病伴心力衰竭患者给予患者美托洛尔治疗,能明显改善患者的血压和心率,未见明显不良反应,用药安全,具有积极的推广价值。Objective: To investigate the efficacy of metoprolol in the treatment of valvular heart disease with heart failure. Methods: 80 cases of patients with valvular heart disease with heart failure, random lottery were divided into control group and observation group(n=40), the control group given conventional treatment, the observation group was given tartrate metoprolol treatment, compared before and after one course of treatment of patients with systolic blood pressure(SBP), diastolic blood pressure(DBP), heart rate and serum BNP, hs-CRP levels. Observe adverse reactions. Results: Compared with before treatment, the above indexes in both groups were decreased(P<0.05), and the heart rate, serum BNP and hs-CRP levels in the observation group were significantly lower than those in the control group(P<0.05). There was no difference between groups in SBP and DBP levels(P>0.05). There was no difference in adverse reactions between the observation group and the control group(P>0.05). Conclusion: Metoprolol can obviously improve the blood pressure and heart rate of patients with valvular heart disease with heart failure, and no obvious adverse reactions were observed.

关 键 词：心脏瓣膜病 心力衰竭 美托洛尔 临床效果 

分 类 号：R541.6[医药卫生—心血管疾病] R542.5[医药卫生—内科学]